Race Oncology (ASX:RAC) filed an application with the Bellberry Human Research Ethics Committee for a phase 1 trial investigating the use of the RC220 bisantrene in combination with doxorubicin to potentially treat solid tumors, according to a Thursday filing made with the Australian bourse.
Once approved, the biopharmaceutical firm will activate the first trial site in New South Wales, with an additional 10 sites to follow, the filing said.
Patient recruitment for the trial is scheduled for the first quarter of next year, the filing added.
The company's shares surged past 9% in recent Thursday trade.
Price (AUD): $1.41, Change: $+0.12, Percent Change: +9.33%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.